Diffuse large B-cell lymphoma (DLBCL) is an aggressive, B-cell non-Hodgkin lymphoma (NHL) that primarily affects the lymph nodes, although it can affect other parts of the body, including the lungs. There are two main ways in which DLBCL can affect the lungs:
Primary pulmonary lymphoma is a rare type of lymphoma that begins in the lungs. In patients with primary pulmonary lymphoma, cancer cells are found only in the lungs and not in any other parts of the body for at least 3 months after the initial diagnosis.
Primary pulmonary lymphomas are rare, accounting for 0.5–1% of all primary lung cancers. It is the second most common form of primary pulmonary lymphoma, representing 11–19% of all cases. It is more common in older patients and patients with a weakened immune system.
The exact way in which primary pulmonary DLBCL begins is not fully understood. Some cases begin as primary pulmonary DLBCL, but it more commonly occurs as a transformation from primary pulmonary marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue or MALT.
Clinical trials in primary pulmonary DLBCL would help identify the best treatment strategy, but due to its rarity, it is challenging to find sufficient patients. Treatment options may include watchful waiting, surgery, chemotherapy, or chemotherapy followed by radiotherapy.
Secondary pulmonary lymphoma is more common than primary pulmonary lymphoma and occurs when lymphoma that begins in other parts of the body spreads to the lungs. Around 24% of non-Hodgkin lymphomas secondarily affect part of the lungs. DLBCL is the most common subtype of secondary pulmonary lymphoma.
Pulmonary DLBCL can be difficult to diagnose due to the non-specific features, which can lead to a misdiagnosis or delayed diagnosis. A CT scan may show signs that the disease is affecting the lungs, such as:
As these signs are not unique to pulmonary DLBCL, a biopsy (a lung sample) may be necessary to confirm a diagnosis.
The symptoms of pulmonary DLBCL are non-specific and can be difficult to distinguish from other diseases. This is why it's important to remember that if you experience any new symptom, it's always a good idea to report it to your doctor, who can rule out any lymphoma complications. Symptoms may include:
When it comes to lymphoma, having a specialist who truly understands the nuances and potential complications of the disease can make all the difference. From identifying early warning signs to navigating treatment options, a knowledgeable specialist can provide invaluable support. Explore HealthTree's lymphoma specialist directory to find one close to you:
Sources:
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, B-cell non-Hodgkin lymphoma (NHL) that primarily affects the lymph nodes, although it can affect other parts of the body, including the lungs. There are two main ways in which DLBCL can affect the lungs:
Primary pulmonary lymphoma is a rare type of lymphoma that begins in the lungs. In patients with primary pulmonary lymphoma, cancer cells are found only in the lungs and not in any other parts of the body for at least 3 months after the initial diagnosis.
Primary pulmonary lymphomas are rare, accounting for 0.5–1% of all primary lung cancers. It is the second most common form of primary pulmonary lymphoma, representing 11–19% of all cases. It is more common in older patients and patients with a weakened immune system.
The exact way in which primary pulmonary DLBCL begins is not fully understood. Some cases begin as primary pulmonary DLBCL, but it more commonly occurs as a transformation from primary pulmonary marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue or MALT.
Clinical trials in primary pulmonary DLBCL would help identify the best treatment strategy, but due to its rarity, it is challenging to find sufficient patients. Treatment options may include watchful waiting, surgery, chemotherapy, or chemotherapy followed by radiotherapy.
Secondary pulmonary lymphoma is more common than primary pulmonary lymphoma and occurs when lymphoma that begins in other parts of the body spreads to the lungs. Around 24% of non-Hodgkin lymphomas secondarily affect part of the lungs. DLBCL is the most common subtype of secondary pulmonary lymphoma.
Pulmonary DLBCL can be difficult to diagnose due to the non-specific features, which can lead to a misdiagnosis or delayed diagnosis. A CT scan may show signs that the disease is affecting the lungs, such as:
As these signs are not unique to pulmonary DLBCL, a biopsy (a lung sample) may be necessary to confirm a diagnosis.
The symptoms of pulmonary DLBCL are non-specific and can be difficult to distinguish from other diseases. This is why it's important to remember that if you experience any new symptom, it's always a good idea to report it to your doctor, who can rule out any lymphoma complications. Symptoms may include:
When it comes to lymphoma, having a specialist who truly understands the nuances and potential complications of the disease can make all the difference. From identifying early warning signs to navigating treatment options, a knowledgeable specialist can provide invaluable support. Explore HealthTree's lymphoma specialist directory to find one close to you:
Sources:
about the author
Dylan Barrett
Dylan is a freelance medical writer based in Cork, Ireland. He previously worked in independent medical education while living in London and is now collaborating with HealthTree to develop resources for blood cancer patients. His background is in genetics, and he has a passion for innovative scientific research. In his spare time, he enjoys sports, traveling, and spending time with his family and friends.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.